Browse drugs

…h anti-IL23-naïve individuals and those previously treated with Ustekinumab, in real-world clinical practice at a tertiary hospital.Materia…

…s evolved with the emergence of new therapeutic targets such as risankizumab. Plasma drug concentrations complement data directly related to…

… the median age was 50 (16-84) years, 53.1% of whom were women. Risankizumab prescriptions were for: PsO (58.4%), CD (30.1%), PsA (10.6%), a…

…re recorded. At the end of follow-up, two patients continued on risankizumab monotherapy, while three maintained the combination therapy.Con…

…KEEPsAKE 2 pooled for prespecified outcomes. Outcomes measuring risankizumab efficacy across key GRAPPA-recognised domains of PsA (periphera…

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…127) of the cohort, of which 12% (n=92) were serious.Conclusion Risankizumab was effective in a large, real-world, medically refractory CD c…

…human TL1A antibody Tulisokibart, anti-human IL-23 p19 antibody Risankizumab, alone or in combination, reduced the weight loss, DAI scores a…

…l surgery.Advanced therapies used for treatment of OFG included adalimumab (n=56), infliximab (n=52), ustekinumab (n=23), risankizumab (n=…

… with well-controlled psoriasis receiving the exemplar biologic risankizumab.Methods and analysis This is a multicentre, assessor-blind, par…

…arthritis was the most frequent diagnosis (30%).Drugs involved: adalimumab (35%), etanercept (25%), certolizumab (8%), belimumab (6%), ixe…

…ent followed by another anti-TNFa treatment or Vedolizumab then Ustekinumab. Median age at diagnosis was 8 years. We found that (40%) switc…